Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Sponsored by Hoffmann-La Roche
About this study
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
Where this study is enrolling (5)
- I'm interested
Grady Memorial Hospital
Atlanta, Georgia
- I'm interested
Accel Research Sites-NeuroStudies
Decatur, Georgia
- Call 888-437-0813
RE:Cognition (Chicago)
Chicago, Illinois
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- I'm interested
Great Lakes Clinical Trials Chicago d/b/a Flourish Research Andersonville
Chicago, Illinois
- Call 888-437-0813
Re:Cognition Health - Houston
Houston, Texas
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
Who can participate
Inclusion criteria
- ✓Ability and willingness to participate in an interventional clinical study, including meeting key eligibility criteria of linked interventional Roche AD studies (e.g., specific age ranges)
- ✓Ability and willingness to receive information about potential eligibility in an associated interventional Roche AD study
Exclusion criteria
- ✕Dependency in basic activities of daily living (bADLs) due to cognitive impairment
- ✕Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)
- ✕Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD
- ✕History of severe, clinically significant central nervous system trauma
- ✕Any serious medical condition that precludes a participant's safe participation and completion of a clinical study
- ✕For participants with a clinical diagnosis of MCI or mild AD: Previous AD diagnosis based on biomarker confirmation with an approved or validated rule in method (e.g., amyloid PET or cerebrospinal fluid, blood biomarker) is exclusionary
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.